Zyban News and Research

RSS

Bupropion (previously known as amfebutamone; Wellbutrin, Zyban) is an atypical antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to the stimulant cathinone, to the anorectic diethylpropion, and to phenethylamines in general. Initially researched and marketed as an antidepressant, bupropion was subsequently found to be effective as a smoking cessation aid.

Augmenting an antidepressant with aripiprazole may help some older adults with treatment-resistant depression

For older adults with clinical depression that has not responded to standard treatments, adding the drug aripiprazole (brand name Abilify) to an antidepressant they're already taking is more effective than switching from one antidepressant to another, according to a new multicenter study led by Washington University School of Medicine in St. Louis.

3 Mar 2023

Study assesses the effectiveness of e-cigarettes as a smoking cessation aid

Using e-cigarettes to stop smoking may result in fewer successful quit attempts than trying to quit using other smoking cessation aids, such as nicotine replacement therapy (NRT) or meds, suggests US research published online in the journal Tobacco Control.

8 Feb 2022

Vaping trends and detrimental effects of e-cigarette usage

In recent news, researchers have found that the liquid used in e-cigarettes, when heated, reacts to form irritating chemicals called acetals, formed from chemicals used to flavor and perfume foods and other commercial products.

31 Jul 2019

New study shows decline in benefits from smoking cessation medications over time

A new Tel Aviv University study published in Addiction finds that only eight out of 100 smokers who take smoking cessation medications will have benefited from taking smoking medications after one year's time.

30 Jan 2018

USA Medical shares 3 tips to help people stick to New Year's resolutions for better health

At the beginning of each new year, many people make resolutions to improve their health; they may aim to lose weight, stop smoking, exercise more, remember to take prescriptions as directed.

28 Dec 2016

Use of nicotine patches or Zyban drug during pregnancy benefits both mother and child

The results of a study conducted by Dr. Anick Bérard, Professor and Fonds de recherche du Québec - Santé Research Chair on Medications and Pregnancy, at the University of Montreal's Faculty of Pharmacy and the Ste-Justine University Hospital demonstrate that the use of nicotine patches or the drug Zyban has positive effects for the unborn child and allows pregnant women to stop smoking during and after pregnancy.

19 Jul 2016

Study finds sex differences in smoking cessation with medications

A new study led by Assistant Medical Professor Philip Smith of The City College of New York's Sophie Davis Biomedical Education/CUNY School of Medicine, and conducted in collaboration with researchers at Yale University and Yeshiva University, found important differences between women and men in their ability to quit smoking when taking medications commonly prescribed to help smokers quit.

17 Jul 2016

Bupropion, varenicline drugs do not increase risk of serious neuropsychiatric adverse events

Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.

25 Apr 2016

Smoking cessation medication 46% effective in women

The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.

8 Oct 2015

New prescription smoking-cessation drug not helping smokers quit

The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine.

18 Aug 2015

Women who take stop-smoking drug Zyban during pregnancy give birth to a child with birth defects

The Arentz Law Group is currently investigating cases of birth defects caused by the stop-smoking drug Zyban. Women who have taken Zyban while pregnant, and given birth to a child born with a birth defect, are encouraged to contact the law firm immediately for a free legal consultation.

7 Jul 2015

Extending use of bupropion before quitting reduces smoking behavior

Smokers may be more likely to successfully quit their habit if simple adjustments were made to how an existing anti-smoking medication is prescribed, according to a new study by a University at Buffalo research team.

3 Mar 2015

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.

17 Jun 2014

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy has found no evidence of an increased risk.

11 Oct 2013

New editorial offers clarity on confusing drug and alcohol addiction terminology

A new editorial released this week offers clarity and structure on confusing drug and alcohol addiction terminology for prescribers, users and regulators. "Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?" is published in the Journal of Psychopharmacology, the official journal of the British Association for Psychopharmacology, published by SAGE.

4 Feb 2012

22nd Century completes enrollment in X-22 Phase II-B smoking cessation study

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.

27 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

22nd Century initiates enrollment in Phase II-B clinical trial of X-22 for smoking cessation

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.

8 Aug 2011

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

22 Jul 2011

22nd Century submits IND to FDA for VLN cigarettes

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.

22 Jun 2011